Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Medtronic
McKinsey
Dow
Colorcon

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Calcipotriene And Betamethasone Dipropionate, and when can generic versions of Calcipotriene And Betamethasone Dipropionate launch?

Calcipotriene And Betamethasone Dipropionate is a drug marketed by Perrigo Uk Finco and Tolmar and is included in two NDAs.

The generic ingredient in CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

Summary for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Drug patent expirations by year for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Recent Clinical Trials for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Celgene CorporationPhase 4
Psoriasis Treatment Center of Central New JerseyPhase 4
Icahn School of Medicine at Mount SinaiPhase 4

See all CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE clinical trials

Pharmacology for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Synonyms for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
485805-18-3
Betamethasone dipropionate and calcipotriene
Betamethasone dipropionate mixture with calcipotriene
Betamethasone dipropionate-calcipotriene mixt.
Calcipotriol/betamethasone dipropionate
Daivobet
Dovobet
Enstilar
LEO 80185
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)-, mixt. with (1alpha,3beta,5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola- 5,7,10(19),22-tetraene-1,3,24-triol
SCHEMBL18863209
Taclonex scalp
Xamiol

US Patents and Regulatory Information for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Uk Finco CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE betamethasone dipropionate; calcipotriene OINTMENT;TOPICAL 200174-001 Dec 12, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Tolmar CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE betamethasone dipropionate; calcipotriene OINTMENT;TOPICAL 201615-001 Jan 14, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Harvard Business School
Medtronic
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.